Based on the ASC4MORE trial, would you add asciminib to imatinib if patients don’t achieve deep molecular remission at 1 year?  

This is hard to justify. If you are using asciminib, the patient likely has had resistance to several prior TKI's. In this setting, treatment discontinuation is not recommended outside of clinical trials. Achieving BCR::ABL1 <=1% is an adequate response likely to improve survival, and about 40% o...

Asciminib is currently not approved to be added on to TKI therapy, including imatinib. It is being studied, as Dr. @Cortes mentions and it may be a strategy in the future. For now, if a patient has a PCR of 1% or less at 1 year on imatinib, I would not change therapy.